Nuvilex Inc. (NASDAQ:PMCB) Short Interest Update

Nuvilex Inc. (NASDAQ:PMCB) saw a large increase in short interest in September. As of September 15th, there was short interest totaling 221,600 shares, an increase of 67.5% from the August 31st total of 132,300 shares. Based on an average daily volume of 87,000 shares, the short-interest ratio is presently 2.5 days. Currently, 3.6% of the company’s stock are sold short. Currently, 3.6% of the company’s stock are sold short. Based on an average daily volume of 87,000 shares, the short-interest ratio is presently 2.5 days.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Nuvilex in a report on Saturday, September 27th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Nuvilex Trading Down 1.9%

NASDAQ PMCB opened at $1.01 on Wednesday. The firm has a market capitalization of $6.87 million, a P/E ratio of -1.87 and a beta of -0.05. The business has a fifty day simple moving average of $0.97 and a 200 day simple moving average of $1.07. Nuvilex has a 12 month low of $0.80 and a 12 month high of $2.42.

Nuvilex (NASDAQ:PMCB) last released its quarterly earnings results on Monday, September 15th. The company reported ($0.09) EPS for the quarter.

About Nuvilex

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.